← SynDRA

NADIDE

SynDRA canonical compound SYN0024310 — structure-anchored drug synonym record

Clinical phasePhase 2
Primary target(s)AASS | ACADS | ADH1A | ADH1B | ADH1C | ADH4 | ADH5 | ADH7 | AKR1B1 | AKR1C1 | AKR1C2 | AKR1C3 | AKR1C4 | ALDH1A1 | ALDH1A2 | ALDH1A3 | ALDH1B1 | ALDH2 | ALDH3A1 | ALDH3A2 | ALDH3B1 | ALDH3B2 | ALDH4A1 | ALDH5A1 | ALDH6A1 | ALDH7A1 | ALDH9A1 | AMT | BDH1 | BLVRA | BLVRB | CDO1 | CYB5R3 | CYP17A1 | CYP4A11 | DHCR7 | DHFR | DLAT | DLD | EHHADH | GAPDH | GAPDHS | GLUD1 | GLUD2 | GPD1 | GSR | H6PD | HADH | HADHA | HIBADH | HMGCR | HMOX1 | HMOX2 | HPGD | HSD11B1 | HSD11B2 | HSD17B1 | HSD17B10 | HSD17B2 | HSD17B3 | HSD17B4 | HSD17B7 | HSD17B8 | HSD3B1 | HSD3B2 | IDH3A | IDH3B | IDH3G | IMPDH1 | IMPDH2 | LDHA | LDHAL6A | LDHAL6B | LDHB | LDHC | MDH1 | MDH2 | ME1 | ME2 | ME3 | MSMO1 | MTHFD1 | MTHFD2 | MT-ND1 | MT-ND2 | MT-ND3 | MT-ND4 | MT-ND4L | MT-ND5 | MT-ND6 | NDUFA1 | NDUFA10 | NDUFA11 | NDUFA12 | NDUFA13 | NDUFA2 | NDUFA3 | NDUFA4 | NDUFA4L2 | NDUFA5 | NDUFA6 | NDUFA7 | NDUFA8 | NDUFA9 | NDUFAB1 | NDUFB1 | NDUFB10 | NDUFB2 | NDUFB3 | NDUFB4 | NDUFB5 | NDUFB6 | NDUFB7 | NDUFB8 | NDUFB9 | NDUFC1 | NDUFC2 | NDUFS1 | NDUFS2 | NDUFS3 | NDUFS4 | NDUFS5 | NDUFS6 | NDUFS7 | NDUFS8 | NDUFV1 | NDUFV2 | NDUFV3 | NNT | NQO2 | NSDHL | OGDH | PDHA1 | PDHA2 | PDHB | PHGDH | PYCR1 | PYCR2 | QDPR | RDH5 | SORD | TSTA3 | TYR | UGDH

All known targets

Mechanisms of action (all sources)

Cross-references

Synonyms

Look up NADIDE in the interactive SynDRA portal →